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ABSTRACT 
Dexamethasone (Dx) is often used in obstetric practice to promote fetal lung maturation and 
to prevent respiratory distress syndrome when the risk of preterm delivery persists. This 
therapy enables survival of the newborn, but also is associated with deleterious effects on the 
offspring, such as reproductive disorders. The aim of this study was to determine specifically 
whether prenatal exposure to Dx disturbs the physiological balance between proliferation and 
apoptosis of germinative cells (GC) in the ovary of 19 and 21 day old fetuses and thus 
induces developmental programing of the female reproductive system. Pregnant Wistar rats 
(n = 10/group), separated into control (vehicle) and Dx-treated (0.5 mg/kg body mass) 
groups, received injections on gestational days 16, 17 and 18. Exposure to Dx lowered the 
volume of the fetal ovary by 30% (p<0.05) in 21 day old fetuses, as well as the total number 
of GC in the ovary by 21% (p<0.05). When compared to the controls, in Dx-exposed fetuses 
the total number of PCNA positive GC was 27% lower at 19 days and 71% lower at 21 day 
old (p<0.05), while total numbers of caspase-3 positive GC were 2.3 fold and 34% higher 
respectively, (p<0.05). Our results demonstrate that prenatal exposure to Dx diminished 
proliferation but increased the rate of germinative cell apoptosis, with consequently reduced 
total germinative cell number and ovary volume. Impairment of fetal oogenesis and fewer GC 
in the fetal ovary compromise the oogonial stock and thus may constitute a risk for female 
fertility. 
 
INTRODUCTION 
Ovary development begins early during fetal life in mammals. This process involves 
segregation of the primordial germ cells (PGC) from the somatic lineages, migration from the 
yolk sac and colonization of the genital ridges, where they continue extensive mitotic 
proliferation reaching a peak value at 18.5 days post conception in rats. Subsequently, mitotic 
activity declines, most oogonia enter meiosis to produce a pool of oocytes arrested at the 
diplotene stage of the first meiotic division, while apoptotic activity resumes [1]. Normal 
ovarian development provides a balance between proliferation and apoptosis of germinative 
cells, which is the major phenomenon in establishing the maximal reproductive potential of 
adult females [2]. 
 
Exposure to drugs during intrauterine life may have an influence on normal progression of 
development of the fetal ovary and the future of adult fertility [2]. Pathological conditions 
during pregnancy involve assessment of the benefits and risks of drug usage, which is 
frequently indispensable, as in the case of glucocorticoids. Glucocorticoids have a strong 
influence on growth and final maturation of fetal organ systems [3]. One of the most 
important events during intrauterine life, which represents a critical developmental trigger, is 
the increase of endogenous fetal glucocorticoids [4]. Endogenous glucocorticoids are 
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essential for normal maturation of the fetal brain and lung as well as developmental switching 
in the pituitary, thyroid gland and kidney [5, 6]. When the risk of preterm delivery persists, a 
pregnant woman needs to be treated with exogenous glucocorticoids to promote 
differentiation and maturation of fetal organ systems, to mimic normal intrauterine conditions 
[7, 8]. Moreover, glucocorticoid application is routine in the prevention and management of 
conditions that threaten maternal and fetal health, such as maternal asthma [9] and 
autoimmune diseases [10]. Dexamethasone (Dx) is considered to be the glucocorticoid of 
choice for antenatal therapy [2]. In addition to its beneficial effects on growth and 
differentiation, the risks of such therapy are well known. Prenatal exposure to Dx is 
associated with several systemic long-term deleterious effects on the offspring, such as 
cardiovascular, metabolic and neuroendocrine disorders [11, 12, 13]. This concept is known 
as developmental programming, and implies linkage between adverse environmental signals 
during prenatal development with a greater incidence of pathophysiological conditions in 
postnatal life [14]. Dx is used in numerous experimental protocols to induce developmental 
programming [11, 15, 16]. Latеly, interest in the field of developmental programming has 
been focused on reproductive dysfunction in adult females and males. 
 
 Our recent results, obtained by exploiting a rat model, indicate that prenatal 
exposure to Dx leads to novel developmental programming of the reproductive system at the 
level of the pituitary gland and ovary. Namely, exposure to Dx during the most vulnerable 
period in pituitary development markedly reduced gonadotropic cell number, which partly 
contributed to diminished volume of the entire gland in rat fetuses [17]. Changes established 
during fetal development are long lasting and persist postnatally throughout neonatal, infant 
and peripubertal periods [18]. Prenatal exposure to Dx also decreased the number of ovarian 
primordial, primary and secondary follicles in neonatal offspring [19], which indicates 
reduced reproductive potential for each female. The aim of the present study was to elucidate 
if this situation is the consequence of a disturbed balance between proliferation and loss by 
apoptosis of germinative cells in the fetal ovary after exposure to Dx. 
 
 Herein, we have investigated the expression of markers of cell proliferation 
(proliferating cell nuclear antigen - PCNA) and apoptosis (caspase-3) in the developing rat 
ovary following exposure to Dx. Estimation of the total number of proliferating germinative 
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cells and germinative cells with signs of apoptosis, using design-based stereology, may 
provide evidence about whether prenatal exposure to Dx impairs development of the rat 
ovary, and thus influences developmental programing of the female reproductive system. 
 
MATERIALS AND METHODS 
Animals and Experimental Groups 
Adult female Wistar rats (average body mass of 200–250 g; bred at the Institute for 
Biological Research “Siniša Stanković”, Belgrade, Serbia) were maintained under controlled 
conditions (12 h:12 h light-dark cycle at 22°C) with food and water available ad libitum. Two 
nulliparous females were mated per fertile male. Detection of sperm in a vaginal smear was 
considered as gestational day (GD) 1. The gravid females were randomized into a control and 
an experimental group, each consisting of 20 animals. During the key period of rat ovarian 
development on days 16, 17 and 18 of pregnancy, each experimental dam received 0.5 mg Dx 
(Dx phosphate dissolved in 0.9% saline (Krka FARMA d.o.o., Belgrade, Serbia)/kg body 
mass (BM) in 0.4 ml s.c.. This dosing regimen was designed to fall within the range of 
clinical exposure in women (0.1–0.5 mg/kg) [20]. The control gravid females received the 
same volume of saline. On days 19 or 21 of gestation pregnant dams were anaesthetized with 
diethylether (Merck, Kenilworth, USA) and the fetuses were removed from the uterus. Their 
sex was determined by external examination (anogenital distance) and the males were 
discarded. One female fetus was randomly chosen from each of the 10 control and 10 litters 
of Dx-treated dams, at 19 and 21 days old. Randomization obviated any potential litter bias. 
The ovaries were excised and fixed with 4% paraformaldehyde for 24 h. After embedding in 
Histowax (Histolab Product AB, Göteborg, Sweden), each tissue block was serially 
sectioned, at 2-μm thickness, on a rotary microtome (RM 2125RT Leica Microsystems, 
Wetzlar, Germany). All animal procedures complied with the European Communities 
Council Directive (86/609/EEC) and were approved by the Ethical Committee for the Use of 
Laboratory Animals of the Institute for Biological Research “Siniša Stanković”, University of 
Belgrade (No. 2-12/13). 
 
Immunohistochemical Analyses 
Expression of proliferating cell nuclear antigen (PCNA) and caspase-3 in the fetal ovaries 
was investigated using immunohistochemical methods [18]. After deparaffinization and 
rehydratation, two-micrometer-thick serial sections were pretreated with citrate buffer for 
antigen retrieval according to standard protocols. For inactivation of endogenous peroxidase, 
0.3% hydrogen peroxidase in methanol was used, followed by incubation with normal 
donkey serum (Abcam, Cambridge, UK, 1:10) for 45 min to reduce nonspecific background 
staining. The samples were then incubated overnight with the primary antibodies: anti-PCNA 
(mouse monoclonal, Abcam, Cambridge, UK, 1:10000) or anti-caspase-3 goat anti-human, 
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Santa Cruz Biotechnology, USA, 1:200). The HRP conjugated secondary antibodies were 
donkey anti-mouse and donkey anti-goat, (Abcam, Cambridge, UK; 1:100). Staining was 
visualized with DAB (3,3’-diaminobenzidine tetrahydrochloride; Dako A/S Glostrup, 
Denmark). As a control for nonspecific binding of the secondary antibody, parallel sections 
were incubated without the primary antibody. 
 
Stereological analysis 
All stereological analyses were performed using a workstation comprising a microscope 
(Olympus BX-51) equipped with a microcator (Heidenhain MT1201), a motorized stage 
(Prior) and a CCD video camera (PixeLink). The main objectives were a planachromatic 
4×dry lens (numerical aperture 0.13), a 40×dry lens (numerical aperture 0.17) and a 100×oil 
lens (numerical aperture 1.30). Control of stage movements and interactive test grids and 
unbiased dissector frames were provided by the newCAST software package. 
 
Volume of fetal ovary 
Fetal ovary volume was estimated using Cavalieri’s principle [21]. Sampling of sections (2 
μm thick) was systematically uniform from the random start. Every 10th section from the 
whole fetal ovary was analyzed (the same sections were used in the subsequent estimation of 
PCNA and caspase-3 positive GC numbers by the physical dissector method). Fetal ovary 
volume was determined by multiplying the sum of the areas by the interval between the 
sections according to the formula: 


 
n
i
PipaV BA
1
/  
where a/p is the area associated with each sampling point within the grid (1671.024μm2); BA 
(block advance) is the mean distance between two consecutively studied sections, i.e. real 
section thickness 2 μm × 10; n is the number of sections studied for each ovary, and ΣPi is 
the sum of points hitting a given target. 
 
Quantification of GC, PCNA and caspase-3 positive germinative cell numbers 
The total numbers of GC and immunostained GC in ovaries from control and Dx-treated 
dams were determined using a fractionator/physical disector design with two levels of 
sampling [19]. 
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Sampling was systematically uniform from a random start [21, 22]. Sections defined 
as section pairs were first captured into a super image. After defining and linking, the pairs 
were aligned by translation and rotation using the montage option in the new-CAST software. 
A ×100 oil immersion objective was used for cell counting. One section in the pair was 
labeled the reference section and the other the ‘look-up’ section. Subsequently, they were 
analyzed in both directions with the reference section also becoming the look-up section. This 
doubles the first sampling fraction from 1/10th to 1/5th (sampling fraction 1(f1) =1/5 = 0.2). 
For estimation of the total number of GC, PCNA and caspase-3 positive GC in fetal ovaries, 
an unbiased counting frame measuring 40 × 40 μm (1,600μm2) was used to ensure 150–200 
cells per animal. After defining tissue boundaries, meander sampling was set to analyze 70% 
of the tissue. Therefore, the sampling fraction 2 was f2 = 0.7. The fields of vision were 
randomly selected and the percentage of tissue analyzed was controlled by the software. 
Additionally, new-CAST software facilitated matching of fields between the reference and 
the look-up section. When the field of vision was selected at the reference section, the 
matching position at the consecutive look-up section was scanned and a matching field of 
vision was generated from four images. GC, PCNA and caspase-3 positive GC were counted 
if their nuclei appeared within the unbiased counting frame applied to the reference section; 
they were not intersected by exclusion boundaries [23] and did not appear in the look-up 
section. Raw counts (Q 
–
) of GC, PCNA and caspase-3 positive GC numbers were multiplied 
by the reciprocals of the sampling fractions to estimate the total numbers of GC, PCNA and 
caspase-3 positive GC per fetal ovary. 
 
GC/PCNA/caspase-3 positive GC (n) = Q 
–
 (GC/PCNA/caspase-3 positive GC) × (1/f1) × 
(1/f2). 
Cytological markers used for GC identification include typical diagnostic parameters 
such as cell size and shape (proportion of dimensions) and nucleus size, shape and position. 
 
Statistical Analysis 
 
All results are expressed as mean values for 10 animals per group (± SD). Data were 
evaluated for normality of distribution using the Kolmogorov-Smirnov test followed by 2-
way analysis of variance (ANOVA), with the age of female fetuses (19 and 21 days) and the 
applied treatment (C and Dx) as factors. The post hoc Bonferroni test was used to determine 
significant differences between groups. The minimum level of statistical significance was set 
at p<0.05. 
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RESULTS 
Fetal body mass 
As shown by 2-way ANOVA, there were significant effects of treatment (C/Dx, F = 211.131; 
p<0.001), age (19/21, F = 1765.190; p<0.001) and treatment × age (C/Dx*19/21, F = 73.837; 
p<0.001) on fetal body mass. Subsequent post hoc analysis revealed that exposure to Dx 
during the last week of fetal development reduced BM of 19 and 21 day old female fetuses by 
20% (p<0.05) and 29% (p<0.05), respectively. From fetal day 19 to 21, BM of control female 
rat fetuses increased 2.7 fold (p<0.05), while in the same period that of Dx exposed fetuses 
increased 2.4 fold (p<0.05, Table 1). Exposure to Dx did not affect litter size or ratio of male 
to female pups (Table 1). 
 
Fetal ovary and germinative cells 
Histological and stereological analysis 
In 19 and 21 day old fetuses, definitive histological organization of the ovaries was not 
established. Germinative cells and somatic cells were arranged in clusters, separated from 
each other by connective tissue cells and blood vessels. The medulla of the ovary was filled 
with dense clusters of oocytes, while somatic cells were rare. In contrast, oocytes were scarce 
at the cortex, whereas epithelial cells were abundant. The germ cells were identified from 
their large size, round and lightly staining nucleus. The widespread distribution of PCNA 
indicated active GC proliferation in the fetal ovary. Apoptotic germ cells were identified as 
large cells that stained for caspase-3 (Figure 1 and 2). Exposure to Dx during this crucial 
period in ovary development did not affect the histological features of the fetal ovary. 
 
 Two way ANOVA showed that treatment, age, and treatment × age significantly 
influenced ovary volume, total number of GC and total number of PCNA and caspase-3 
positive GC in the ovaries of 19 and 21 day old fetuses (Table 2). Applying Cavalieri’s 
principle, we calculated that the fetal ovary volume in 19 day old control fetuses was 4 x 10
-2 
± 3 x 10
-4
 mm
3
. Post hoc analysis revealed that Dx exposure did not affect ovary volume in 
19 day old fetuses, while in 21 day old fetuses it was reduced by 30% (p<0.05) when 
compared to controls. As a result of near term physiological processes control fetal ovaries 
increased in volume by 49% between fetal days 19 and 21 (p<0.05, Fig. 3). 
 
 Using the fractionator/physical disector design we estimated that the total number 
of GC per ovary of 19 day old control fetuses was 3892 ± 63 cells, among which there were 
2530 ± 146 PCNA positive GC and 428 ± 12 casp-3 positive GC. The post hoc test showed 
that Dx exposure did not affect the total number of GC in 19 day old fetal ovaries, while the 
total number of PCNA positive GC per ovary was 27% lower (p<0.05), and the total number 
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of casp-3 positive GC had increased 2.3 fold (p<0.05) when compared to controls (Table 3). 
In 21 day old fetuses exposure to Dx had reduced the total number of GC by 21% (p<0.05), 
as well as the total number of PCNA positive GC by 71% (p<0.05). Administration of Dx 
raised the total number of casp-3 positive GC by 34% (p<0.05) in comparison to control 
values (Table 3). Thus, from fetal day 19 to 21 the total numbers of GC, PCNA and casp-3 
positive GC were significantly diminished by 57% (p<0.05), 84% (p<0.05) and 50% 
(p<0.05), respectively (Table 3). 
 
 In the ovaries of control 19 day old fetuses the relative numbers of PCNA and 
caspasa-3 positive/total GC (labeling index) were 65% and 11%, respectively. After Dx 
exposure the percentage of PCNA positive/total GC declined to 48%, while that of casp-3 
positive /total GC increased to 25% (Figure 4). Between fetal day 19 and 21 relative numbers 
of PCNA and casp-3 positive/total GC cells reach to 25% and 13%, respectively, in control 
fetuses. Dx exposure enhanced the drop in proportion of PCNA positive/total GC cells in 21 
day old fetuses to 9%, but increased that of casp-3 positive/total GC cells to 22% (Figure 4). 
 
DISCUSSION 
This work represents an experimental demonstration in vivo of the potential harmful effect of 
Dx exposure on the rat fetal ovary. Using a modern stereological approach, we demonstrated 
that Dx exposure decreased the volume of the fetal ovary and the proliferation rate of 
germinative cells, while it increased their apoptotic rate. Accordingly, Dx lowered the 
number of germinative cells in the rat fetal ovary, which can be linked with reduced 
reproductive potential in adulthood. 
 
The fetal period is critical for ovary development and future adult fertility, since the 
final number of oocytes accessible for reproduction of the next generation is mostly defined 
at that time [2]. An important target of developmental programming is the reproductive 
system. If adverse impacts are experienced at a critical timeframe during fetal life, normal 
dynamics of the developmental process in the ovary may be changed, with long-term effects 
on ovary structure and function. 
 
 Under our experimental conditions overexposure to glucocorticoids caused 
intrauterine growth retardation, followed by reduced body mass of 21 day old female fetuses. 
Body mass is a crucial determinant of fetal growth. Low birth mass, as a marker of adverse 
environmental signals during prenatal development, is associated with increased frequency of 
pathophysiological conditions in adulthood [14]. An excessive level of glucocorticoids during 
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fetal life disturbs development of body weight regulatory systems and such alterations 
continue until prepuberty [16]. Low birth mass and durable reduced body mass in female 
offspring prenatally exposed to glucocorticoids may be related to delayed onset of puberty 
[24, 25], indicating that body mass is an essential component of reproductive maturation. 
 
Ovarian development during fetal life is a complex phenomenon determined by 
successive changes in cell kinetics. Progressive growth of germinative cells, as differentiation 
proceeds, and enlarged proliferation of follicular cells [26] contribute to the increased ovarian 
volume in the same period. Periods of rapid GC proliferation are followed by stages of 
stability and greater rates of apoptosis. High mitotic activity of oogonia was detected in our 
experimental conditions using the PCNA immunomarker. The widespread distribution of 
PCNA indicated active cell proliferation in the ovary of 19 day old fetuses. However, the 
decline in percentage of PCNA positive/total GC between fetal days 19 and 21 correlated 
with transition from mitosis to meiosis, i.e. from oogonia to primary oocytes. 
 
 Besides GC proliferation, an essential component of ovarian development is 
apoptosis. Prenatal loss of oocytes reflects selection at the cellular level and provides 
regulation of the size and quality of the germinative cell pool that will define reproductive 
potential of the individual [27]. Apoptosis occurs at all stages of oogenesis, with three main 
waves of loss described until primordial follicle formation [28]. The first wave appears at the 
oogonial stage and affects up to 3.6% of GC. We documented the second wave of loss in 19 
day old fetuses, when oogonia cease mitosis and enter meiosis and the apoptotic rate of GC 
reaches 11%. Degeneration of germinative cells continues up to 48 hours after birth, when a 
third wave of degeneration occurs just before the formation of primordial follicles. In that 
period, the oocytes are in late pachiten [28]. The balance between apoptosis and proliferation 
during fetal ovarian development is the crucial phenomenon for establishing maximal 
reproductive potential in adulthood, since the overall number of oocytes is defined during the 
fetal period. 
 
 Dexamethasone is often used in obstetric practice to promote fetal lung maturation 
and to prevent respiratory distress syndrome, when the risk of preterm delivery persists [29]. 
Several epidemiological studies using Dx as prenatal treatment have shown that it does not 
have a teratogenic effect when applied according to the usual protocol [30, 31]. However, the 
effect of Dx on the fetal ovary and long-term fertility of women exposed in utero is unknown, 
as Dx treatment was initiated in the early 1980s. Therefore, animal studies can greatly 
illuminate this very important aspect of female reproduction. 
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 Exposure to Dx during the most vulnerable period in ovary development decreased 
the relative number of PCNA positive germinative cells, while increasing that of caspase-3 
positive germinative cells. Dx lowered the expression levels of v-kit Hardy-Zuckerman 4 
feline sarcoma viral oncogene homolog (KIT) [2]. KIT is crucial for germinative cell survival 
[32] and reduction in KIT expression contributes to Dx-induced germinative cell apoptosis in 
the human female fetal germline [2]. Accelerated apoptosis of germinative cells may lead to 
an imbalance of cell proliferation and death, resulting in impaired oogenesis. Impairment of 
fetal oogenesis through an apoptotic mechanism after Dx exposure reduces the total number 
of GC in the fetal ovary, compromises the oogonial stock and thus may constitute a risk for 
female fertility. 
 
 Our data indicate that prenatal exposure to Dx reduces rat ovary volume and 
number of germinative cells in the fetal ovary. In accordance with the central dogma of 
mammalian reproductive biology, the number of oocytes at birth represents almost the 
complete reproductive potential of an individual. Fewer oocytes in the fetal rat ovary due to 
Dx exposure leads to a significant decrease of the overall follicle number in neonatal rat 
ovaries, as we reported earlier [19]. These data document the programming effect of Dx at 
the level of the ovary. Clear programming effects of Dx were also detected in the 
hypothalamus and pituitary gland [33, 17, 18]. Dx induced changes at all three levels of the 
hypothalamo-pituitary-gonadal axis may contribute seriously to impaired reproductive 
function during adulthood. It is clear that treating pregnant women with drugs, especially 
with those of hormonal nature which cross the placental barrier and may affect fetal 
development, requires a cautious approach. The short medical history of Dx use and lack of 
wide-ranging epidemiological studies elaborating the potential harmful effects of Dx 
treatment during pregnancy on the reproductive system of female offspring indicate that our 
findings have important implications for humans. 
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Table 1.Litter size, female:male ratio, body mass in 19 and 21 day old control fetuses (C) and 
fetuses exposed to dexamethasone (Dx). 
                   Litter size  Female:male  Fetal body mass (g)      
                                         ratio           19 day       21 day 
C 12±3 1:1±0.5 1.5±0.1 4.1±0.5
b
 
Dx 12±2 1:1±0.3 1.2±0.2
a
 2.9±0.3
a,c
 
All results are given as mean ± SD, n=10, 
a
p<0.05, Dx vs. corresponding control; 
b
p<0.05, 
C21 vs. C19, 
c
p<0.05, Dx21 vs. Dx19 (Bonferroni test) 
 
 
 
 
Table 2. Results of the two way ANOVA 
 
 Df Ovary volume GC PCNA+GC Casp-3+GC 
treatment 1 
F=125.6 
p<0.001 
F=134.6 
p<0.001 
F=405.3 
p<0.001 
F=2640.8 
p<0.001 
age 1 
F=173.2 
p<0.001 
F=22409.8 
p<0.001 
F=6356.8 
P<0.001 
F=5547.4 
p<0.001 
treatment×age 1 
F=26.6 
p<0.001 
F=95.9 
p<0.001 
F=61.6 
P<0.001 
F=1510.8 
p<0.001 
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Table 3.Total number of germinative cells, PCNA positive and caspase-3 positive 
germinative cells in ovary of 19 and 21 day old control fetuses (C) and fetuses exposed to 
dexamethasone (Dx). 
 Σ GC Σ PCNA + Σ casp-3 + 
C19 3892±63 2530±146 428±12 
Dx19 3863±48 1854±35
a
 966±24
a
 
C21 1661±39
b
 415±24
b
 216±23
b
 
Dx21 1320±49
a
 119±13
a
 290±12
a
 
All results are given as mean ± SD, n=10, 
a
p<0.05, Dx vs. corresponding control; 
b
p<0.05, 
C21 vs. C19 (Bonferroni test) 
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Figure 1. 
 
Figure 1. Immunohistochemical localization of PCNA and caspase-3 positive germinative 
cells in ovary of 19 day old control fetuses (C) and fetuses exposed to dexamethasone (Dx); 
scale bar- 55μm (a, b) and 20 μm (c, d) 
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Figure 2. 
 
Figure 2. Immunohistochemical localization of PCNA and caspase-3 positive germinative 
cells in ovary of 21 day old control fetuses (C) and fetuses exposed to dexamethasone (Dx); 
scale bar-55μm (a, b) and 20 μm (c, d) 
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Figure 3. 
 
Figure 3. Volume of fetal ovary in 19 and 21day old control fetuses (C) and fetuses exposed 
to dexamethasone (Dx). All results are given as mean ± SD, n=10, 
a
p<0.05, Dx vs. 
corresponding control, 
b
p<0.05, C21 vs. C19 (Bonferroni test) 
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Figure 4. 
 
Figure 4: Graphical presentation of PCNA and caspase-3 labeling index in germ cells, and 
remaining germinative cells, in the developing ovary of 19 and 21 day old control fetuses (C) 
and fetuses exposed to dexamethasone (Dx) 
 
 
 
 
 
 
 
 
 
 
 
 
